These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 39111832)

  • 21. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
    Song Y; Liu Q; Zuo T; Wei G; Jiao S
    Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
    Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
    Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
    Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
    Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
    Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
    Hänsch L; Peipp M; Mastall M; Villars D; Myburgh R; Silginer M; Weiss T; Gramatzki D; Vasella F; Manz MG; Weller M; Roth P
    Neuro Oncol; 2023 Nov; 25(11):2001-2014. PubMed ID: 37335916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.
    Kang CH; Kim Y; Lee SM; Choi SU; Park CH
    Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
    Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
    Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.
    Chokshi CR; Shaikh MV; Brakel B; Rossotti MA; Tieu D; Maich W; Anand A; Chafe SC; Zhai K; Suk Y; Kieliszek AM; Miletic P; Mikolajewicz N; Chen D; McNicol JD; Chan K; Tong AHY; Kuhlmann L; Liu L; Alizada Z; Mobilio D; Tatari N; Savage N; Aghaei N; Grewal S; Puri A; Subapanditha M; McKenna D; Ignatchenko V; Salamoun JM; Kwiecien JM; Wipf P; Sharlow ER; Provias JP; Lu JQ; Lazo JS; Kislinger T; Lu Y; Brown KR; Venugopal C; Henry KA; Moffat J; Singh SK
    Nat Med; 2024 Oct; 30(10):2936-2946. PubMed ID: 39095594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
    Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
    Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.
    Sengupta S; Katz SC; Sengupta S; Sampath P
    Cancer Lett; 2018 Oct; 433():131-139. PubMed ID: 29959057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells.
    Qi C; Liu D; Liu C; Wei X; Ma M; Lu X; Tao M; Zhang C; Wang X; He T; Li J; Dai F; Ding Y; Shen L
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39366753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation CAR T cell therapies for glioblastoma.
    Bernstock JD; Gerstl JVE; Valdés PA; Friedman GK; Chiocca E
    Sci Transl Med; 2024 Aug; 16(762):eadp2660. PubMed ID: 39196960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
    Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
    Immunology; 2024 Jul; 172(3):362-374. PubMed ID: 38469682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma.
    Saleh HA; Mitwasi N; R Loureiro L; Kegler A; Soto KEG; Hoffmann L; Crespo E; Arndt C; Bergmann R; Bachmann M; Feldmann A
    Cancer Gene Ther; 2024 Sep; 31(9):1323-1334. PubMed ID: 38582787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.